No Data
No Data
Express News | Incannex Healthcare Commences Dosing In Phase 2/3 Clinical Trial Assessing IHL-42X In Obstructive Sleep Apnea
Express News | Patient Dosing Commenced in Reposa Phase 2/3 Clinical Trial Protocol to Assess Ihl-42X Drug in Patients With Obstructive Sleep Apnea
Why Incannex Healthcare's (NASDAQ:IXHL) Earnings Are Weaker Than They Seem
Investors were disappointed with Incannex Healthcare Inc.'s (NASDAQ:IXHL) recent earnings release. We did some digging and found some underlying numbers that are worrying. NasdaqGM:IXHL Earnings a
10-Q: Quarterly report
FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder
Incannex Healthcare Inc. (NASDAQ:IXHL), a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food a
Express News | Incannex Complete Successful Pre-IND Meeting With The FDA For CannQuit-O For Treatment Of Opioid Use Disorder
No Data